Ticagrelor: Clinical Trials

410 trials of Ticagrelor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

250 completed, 87 unknown, 29 recruiting, 19 terminated. 190 Phase 4, 84 Phase 3, 42 Phase 2, 38 Phase 1, 33 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 4190Completed 115, Unknown 44, Recruiting 13, Terminated 9, Withdrawn 6, Active not recruiting 2, Not yet recruiting 1
Phase 384Completed 46, Unknown 17, Recruiting 9, Terminated 7, Withdrawn 4, Active not recruiting 1
Phase 242Completed 29, Unknown 7, Terminated 4, Not yet recruiting 1, Withdrawn 1
Phase 138Completed 34, Unknown 3, Not yet recruiting 1
Not applicable33Completed 14, Unknown 9, Active not recruiting 5, Recruiting 5
Early Phase 11Completed 1

Follow Ticagrelor: new trials by email Literature Review of Ticagrelor trials Research Report on Ticagrelor

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combined Antiplatelet Strategy in Acute Ischemic Stroke Following Thrombectomy and/or Intravenous Thrombolysis (CoPRIME)
Aspirin + Clopidogrel, Aspirin, Aspirin + Ticagrelor - Acute Ischemic Stroke
Phase 2Not yet recruitingUniversity of Alberta3002027-01-012026-11-13
Short-Term Dual Antiplatelet Therapy With Early Transi-tion to Low-dose Antiplatelet Monotherapy Using Ti-cagRelor in Chronic Coronary Artery Disease
Ticagrelor 60 mg, clopidogrel 75 mg - Chronic Coronary Syndrome
Phase 4Not yet recruitingUniversity of Messina10002026-11-012026-09-15
Dual Antiplatelet Therapy Strategies After Acute Myocardial Infarction Undergoing PCI: Prasugrel vs Ticagrelor & 12 Months vs 1-3 Months
Prasugrel, Ticagrelor - Myocardial Infarction (MI)
Phase 4RecruitingInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz81002026-09-022026-09-09
Ticagrelor-Based Dual Antiplatelet Therapy Duration in CABG
Ticagrelor + Aspirin for 3 Months (followed by aspirin monotherapy), Ticagrelor + Aspirin for 6 Months (followed by aspirin monotherapy), Ticagrelor + Aspirin for 12 Months (followed by aspirin monotherapy) - Coronary Artery Disease, Coronary Artery Bypass Grafting
Not applicableRecruitingKexiang Liu, MD3002026-05-012026-11-19
Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.
Clopidogrel, Ticagrelor, Prasugrel - Coronary Artery Disease, Percutaneous Coronary Intervention
Phase 3RecruitingCardiocentro Ticino3552026-04-202026-05-13
Long-Term Sequential Dual Antiplatelet Therapy Based on Cilostazol in Symptomatic Intracranial Arterial Stenosis
Cilostazol, Aspirin, Clopidogrel - Ischemic Stroke, Symptomatic Intracranial Atherosclerotic Stenosis
Phase 4RecruitingSecond Affiliated Hospital of Soochow University4802026-03-212026-11-12
Aspirin-free Strategy With Ticagrelor in Patients With a Myocardial Infarction Treated Medically Alone
Ticagrelor + placebo, Ticagrelor + aspirin - NSTEMI - Non-ST Segment Elevation MI, STEMI (ST Elevation MI)
Phase 3RecruitingMontreal Heart Institute25702026-03-032026-03-10
Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteers
AL3818 Capsule, Itraconazole capsule, Ticagrelor Tablets - Healthy Volunteer
Phase 1Not yet recruitingAdvenchen Laboratories Nanjing Ltd.162026-03-022026-02-27
Aspirin 50mg vs 100mg Combined With P2Y12 Inhibitor After PCI
Aspirin, P2Y12 inhibitor - Coronary Artery Disease, Acute Coronary Syndromes
Not applicableRecruitingJilin University26402026-03-012026-10-01
Use and Costs of P2Y12 Inhibitors After Acute Myocardial Infarction
Clopidogrel, Prasugrel, Ticagrelor - Acute Myocardial Infarction (AMI)
CompletedBrigham and Women's Hospital3777532025-11-012026-07-09
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy in Symptomatic ICAD
Point-of-Care CYP2C19 Testing, ticagrelor + aspirin, clopidogrel + aspirin - Intracranial Atherosclerosis
Not applicableRecruitingSunnybrook Health Sciences Centre1002025-10-072025-11-20
Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study
PFO closure using approved PFO closure devices, Surgical PFO closure, Medical management - Ischemic Stroke, Patent Foramen Ovale
Not yet recruitingNational University Hospital, Singapore10002025-07-012025-05-21
IndObufen Versus asPirin After Coronary Drug-eluting Stent implantaTION in Elderly Patients With Acute Coronary Syndrome
Indobufen, Aspirin, Ticagrelor - Coronary Artery Disease, Antiplatelet Drugs
Phase 4RecruitingShanghai Zhongshan Hospital28462025-05-192026-03-12
Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.
Aspirin, Clopidogrel, Ticagrelor - Thrombosis, Bleeding
Active not recruitingPetrovsky National Research Centre of Surgery5002025-05-012026-01-22
Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease
Aspirin, Clopidogrel, Ticagrelor - Peripheral Arterial Disease (PAD), Amputation
Not applicableRecruitingMassachusetts General Hospital4842025-04-292026-09-11
Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination.
A1: Ticagrelor / Acetylsalicylic acid in fixed dose combination capsule. (Laboratorios Silanes S.A. de C.V.), A2: Ticagrelor (BRILINTA®, AstraZeneca S.A. de C.V.) A3: Acetylsalicylic Acid (ASPIRINA JUNIOR®, Bayer de México S.A. de C.V.) - Healthy
Phase 1CompletedLaboratorios Silanes S.A. de C.V.242025-01-132026-03-02
Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors
Ticagrelor 90 mg, Prasugrel 10 mg - Coronary Artery Disease
Phase 4RecruitingUniversity of Florida482025-01-082026-11-18
Colonoscopy and Antiplatelet Therapy Trial
Aspirin, P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel) - Coronary Arterial Disease (CAD), Peripheral Vascular Disease
Phase 4UnknownOchsner Health System1002024-10-012024-09-25
ACT-GLOBAL Adaptive Platform Trial for Stroke
Standard-dose intravenous tenecteplase, Low-dose intravenous tenecteplase, No intravenous tenecteplase - Stroke
Phase 3RecruitingThe George Institute200002024-09-262026-11-10
Study to Assess Pharmacokinetics, Pharmacodynamics and Safety of Tiprogrel in Healthy Subjects
Tiprogrel, Clopidogrel, Ticagrelor - Acute Coronary Syndrome, Ischemic Stroke
Phase 1CompletedTianjin Institute of Pharmaceutical Research Co., Ltd142024-09-092025-01-06

Showing 20 of 410. Sign in to see all of them.

Conditions studied

Coronary Artery Disease (99)  ·  Acute Coronary Syndrome (90)  ·  Myocardial Infarction (43)  ·  ST Elevation Myocardial Infarction (37)  ·  Ischemic Stroke (22)  ·  Cardiovascular Diseases (19)  ·  Thrombosis (18)  ·  Angina, Unstable (14)  ·  Diabetes Mellitus (14)  ·  Stroke (14)  ·  Coronary Disease (12)  ·  Hemorrhage (11)  ·  Atrial Fibrillation (10)  ·  Non-ST Elevated Myocardial Infarction (10)  ·  Peripheral Arterial Disease (10)

Sponsors

AstraZeneca (43)  ·  University of Florida (20)  ·  University of Patras (12)  ·  First Affiliated Hospital of Harbin Medical University (10)  ·  Kafrelsheikh University (10)  ·  Collegium Medicum w Bydgoszczy (9)  ·  Dong-A University (6)  ·  Medical University of Vienna (6)  ·  Assiut University (5)  ·  Beijing Anzhen Hospital (5)  ·  Ottawa Heart Institute Research Corporation (5)  ·  Vastra Gotaland Region (4)  ·  Beijing Tiantan Hospital (3)  ·  Boehringer Ingelheim (3)  ·  Brigham and Women's Hospital (3)

Countries

United States (98)  ·  China (75)  ·  South Korea (43)  ·  Canada (35)  ·  Italy (30)  ·  United Kingdom (30)  ·  Germany (27)  ·  Poland (26)  ·  Spain (26)  ·  Netherlands (25)  ·  France (21)  ·  Greece (21)  ·  Sweden (19)  ·  Brazil (18)  ·  Austria (17)

Top investigators

Dominick J Angiolillo, MD, PhD (6)  ·  Dominick Angiolillo, MD, PhD (4)  ·  Dominick J Angiolillo, MD,PhD (4)  ·  Dimitrios Alexopoulos, MD (3)  ·  Dominick Angiolillo (3)  ·  Glenn Carlson, MD (3)  ·  Jacek Kubica, MD., PhD. (3)  ·  Juan J Badimon, PhD (3)  ·  Judith Hsia, MD (3)  ·  Kathleen Butler, MD (3)  ·  Massoud Leesar, MD (3)  ·  Anders Berggren, MD, PhD (2)  ·  Chunjian Li, Ph.D (2)

Results publications

PMID 35224730, PMID 31867054, PMID 19717846, PMID 2375765, PMID 27160944, PMID 40875095, PMID 18190818, PMID 19923168, PMID 20194878, PMID 30621974, PMID 34515113, PMID 11519503, PMID 15738352, PMID 16731270, PMID 20079528, PMID 21079055, PMID 21545948, PMID 21873419, PMID 22212857, PMID 22795280, PMID 23491524, PMID 23500251, PMID 24291273, PMID 24449597, PMID 24768873, PMID 25175921, PMID 25773268, PMID 27160892, PMID 29915123, PMID 30015064, PMID 31475799, PMID 31535314, PMID 33032710, PMID 33227548, PMID 34473343, PMID 36942550, PMID 37489818, PMID 11786451, PMID 11914403, PMID 12020339, PMID 12435254, PMID 12796140, PMID 12807523, PMID 12832332, PMID 14504252, PMID 14517152, PMID 14602724, PMID 15596563, PMID 15603245, PMID 16046311

NIH funding

2014 (7), 2015 (3), 2016 (3), 2023 (3), 2019 (2), 1OT2HL156812-01 (1), 2009 (1), 2017 (1), 2018 (1), R21AG077310 (1), U01HL128606 (1), U01NS117450 (1), U54MD010723 (1)